The effect of sarcopenic obesity on glycaemic status based on fasting plasma glucose and glycated haemoglobin: A prospective cohort study

Yiling Lou,Yulin Xie,Qingqing Jiang,Shen Huang,Xiaohan Wang,Linlin Wang,Hengchang Wang,Shiyi Cao
DOI: https://doi.org/10.1111/dom.16016
2024-10-23
Diabetes Obesity and Metabolism
Abstract:Aim To investigate the effect of sarcopenic obesity on the progression of glycaemic status in middle‐aged and older adults without diabetes. Materials and Methods This research involved 4637 participants without diabetes from the China Health and Retirement Longitudinal Study 2011–2015. Sarcopenic obesity at baseline was evaluated based on the Asian Working Group for Sarcopenia 2019 criteria. According to the American Diabetes Association criteria, we used fasting plasma glucose and glycated haemoglobin to define glycaemic status. Cox proportional hazard models were applied to obtain adjusted hazard ratios (HRs) and 95% confidence intervals (CIs). Results The mean age of included participants was 58.98 ± 8.82 years, and 45.35% were men. During 18,497 person‐years of follow‐up, 1743 (37.59%) cases with glycaemic status progression were identified. Compared with participants without sarcopenia and obesity, participants with sarcopenic obesity, but not sarcopenia only or obesity only, exhibited a higher risk of progression from normoglycaemia to diabetes (HR = 2.11; 95% CI: 1.10–4.04). Moreover, participants with sarcopenic obesity (HR = 1.65; 95% CI: 1.04–2.63), sarcopenia only (HR = 1.78; 95% CI: 1.11–2.86), or obesity only (HR = 2.00; 95% CI: 1.29–3.12) had increased the risk of progression from prediabetes to diabetes. Conclusions The effect of sarcopenic obesity on the progression of glycaemic status based on fasting plasma glucose and glycated haemoglobin may be more pronounced than that of sarcopenia only or obesity only.
endocrinology & metabolism
What problem does this paper attempt to address?